The DOI matches its Crossref record; 184 of the 192 references it cites were found in a registry or an index; 48 of the 182 sources its claims cite were checked for support.
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Open accessAbstract
Fungal diseases kill more than 1.5 million and affect over a billion people. However, they are still a neglected topic by public health authorities even though most deaths from fungal diseases are avoidable. Serious fungal infections occur as a consequence of other health problems including asthma, AIDS, cancer, organ transplantation and corticosteroid therapies. Early accurate diagnosis allows prompt antifungal therapy; however this is often delayed or unavailable leading to death, serious chronic illness or blindness. Recent global estimates have found 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of Pneumocystis jirovecii pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma and ~1,000,000 cases of fungal keratitis occur annually. Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population). These studies have shown differences in the global burden between countries, within regions of the same country and between at risk populations. Here we interrogate the accuracy of these fungal infection burden estimates in the 43 published papers within the LIFE initiative.
Overview
CoChat Summary
TL;DR
This review interrogates the accuracy of global and multi-national estimates of serious fungal disease burden generated through the Leading International Fungal Education (LIFE) initiative. It summarizes estimates from 43 published country reports and highlights wide variation, data gaps, and likely underestimation of fungal disease burden.
Key findings
- Recent global estimates include 3,000,000 cases of chronic pulmonary aspergillosis, ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS, ~700,000 cases of invasive candidiasis, ~500,000 cases of *Pneumocystis jirovecii* pneumonia, ~250,000 cases of invasive aspergillosis, ~100,000 cases of disseminated histoplasmosis, over 10,000,000 cases of fungal asthma, and ~1,000,000 cases of fungal keratitis annually.
- Across LIFE country papers, candidaemia burden was 159,253 cases in 39 countries, invasive aspergillosis was 81,927 cases in 40 countries, and *Pneumocystis jirovecii* pneumonia was 133,487 cases in 40 papers; the highest candidaemia prevalence was reported in Pakistan (38,795 cases, 21 per 100,000).
- Chronic pulmonary aspergillosis estimates were highest in India (209,147) and Nigeria (120,753), with an overall incidence of 22 cases per 100,000 (14.2–30.59 95% CI); ABPA was estimated at 3,550,157 cases and SAFS at 4,125,428 cases across 43 countries.
- Tinea capitis was estimated at 21,073,423 cases in just 16 countries, with Nigeria alone accounting for 15,581,400 cases; global recurrent vulvovaginal candidiasis prevalence was estimated at about 134,000,000 cases.
Methods
- Narrative review of 43 published papers within the LIFE initiative, covering >2000 million people (29% of the world population), with the LIFE portal having facilitated estimates for over 5.7 billion people (>80% of the world’s population).
- The paper describes how country-level burden estimates were derived for specific fungal diseases, using published epidemiological data, modelling assumptions, and at-risk population denominators.
- Main analysis is descriptive and comparative: it aggregates country estimates, examines differences by region, country, and at-risk group, and discusses strengths and weaknesses of the estimation methods.
Limitations
- The paper states that a precise estimate of global prevalence and incidence for each fungal infection remains unknown, and data are scanty in most countries, especially in the developing world.
- It states that knowledge is impaired by lack of regular national surveillance, no obligatory reporting of fungal diseases, poor clinician suspicion outside specialised units, poor diagnostic test performance, and few well-designed published studies; estimates are not intended as a substitute for high-quality epidemiological study or comprehensive surveillance.
- It also states that comparisons across countries are difficult because recent local epidemiological data were available for only some countries, data quality varies, not all institutions report infections, and many low- and low-middle-income countries lack blood culture systems; the text makes evident that country estimates rely on heterogeneous assumptions and uniform rates in places, such as 5 per 100,000 for candidaemia when local data were unavailable and 6% for recurrent vulvovaginal candidiasis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
33 Valid · 8 Not valid · 70 Not checked · 75 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“In particular, resistance to fluconazole is common [30,43,44]”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
What the sources say
- Not checked — no full text of the sourcecites [30] Arendrup, 2013, Candida and Candidaemia: Susceptibility and Epidemiology, Dan. Med. J.
- Disputedcites [43] Hii, 2015, Changing epidemiology of candidemia in a medical center in middle Taiwan, J. Microbiol. Immunol. Infect. sourceExperimental — accuracy not yet measured
The Discussion reports an overall fluconazole resistance rate of 4.95% among the clinical Candida isolates, contrary to the unqualified claim that resistance is common. The Antifungal susceptibility section distinguishes resistance from reduced susceptibility: only 4.4% of C. glabrata isolates were resistant, although 66.7% were dose-dependent susceptible. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [44] Farahat, 2014, Predictors and outcomes of Candida bloodstream infection: Eight-year surveillance, western Saudi Arabia, Int. J. Infect. Dis. source
The Discussion describes a high level of fluconazole resistance as alarming. The Results report low in vitro susceptibility among Candida bloodstream isolates in the hospital studied, supporting the claim in that setting. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Modelling with existing outcome data shows that mortality associated with these priority fungal diseases concurrently with the Joint United Nations Program on HIV/AIDS (UNAIDS) 90-90-90 campaign could save over 1.6 million lives of persons living with HIV globally over the next five years [2].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Supportedcites [2] Denning, D.W. (2016). Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized. Philos. Trans. R. Soc. B, 371. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The burden of infectious (all-cause, including fungal) keratitis in Mexico was estimated based on the prevalence of reported in China (0.148%) [150].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.6. Fungal Keratitis
What the sources say
- Supportedcites [150] Cao, 2014, Prevalence of infectious keratitis in Central China, BMC Ophthalmol. source
The Abstract Results report an infectious keratitis prevalence of 0.148% in Central China and separately include fungal keratitis among its causes. The Mexico estimate is the citing authors’ use of that figure, not a result attributed to this source. (LLM, conf=0.92)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated the estimation of the burden of serious fungal infections country by country for over 5.7 billion people (>80% of the world’s population).”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > Abstract
What the sources say
- Partly supportedcites [14] Denning, 2017, Calling upon all public health mycologists, Eur. J. Clin. Microbiol. Infect. Dis. sourceExperimental — accuracy not yet measured
The paper describes systematic country-by-country estimates of serious fungal infections and links to the LIFE site for completed estimates (p. 1). It does not state that the portal facilitated this work since 2013 or that the estimates covered over 5.7 billion people (>80% of the world’s population); its stated figure of 883 million people refers only to the current 14-country series (p. 1). (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma and the increasing incidence of cancers are the major drivers of fungal infections in both developed and developing countries globally [1,2,3,4,5,6].”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [1] Brown, 2012, Hidden Killers: Human Fungal Infections, Sci. Transl. Med. source
- Partly supportedcites [2] Denning, D.W. (2016). Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500,000 by 2020 to be realized. Philos. Trans. R. Soc. B, 371. sourceExperimental — accuracy not yet measured
The Introduction identifies major fungal diseases complicating HIV, and the section on chronic pulmonary aspergillosis complicating tuberculosis in HIV-positive patients names TB and COPD as underlying pulmonary disorders (page unavailable). The paper does not identify asthma or increasing cancer incidence as drivers, nor does it establish that the listed conditions are the major drivers of fungal infections globally across developed and developing countries. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [3] Meintjes, 2014, A neglected epidemic: Fungal infections in HIV/AIDS, Trends Microbiol. source
- Not checked — no full text of the sourcecites [4] Guinea, 2010, Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome, Clin. Microbiol. Infect. source
- Not checked — no full text of the sourcecites [5] Marr, 2002, Invasive aspergillosis in allogeneic stem cell transplant recipients: Changes in epidemiology and risk factors, Blood source
- Not checked — no full text of the sourcecites [6] Limper, A.H., Adenis, A., Le, T., and Harrison, T.S. (2017). Fungal infections in HIV/AIDS. Lancet Infect. Dis. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
52 more claims · 6 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 80
- It may state two separate claims as one. 82
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the target organ of A. fumigatus is the lungs, Aspergillus is known to be angiotropic and has an affinity for host vasculature. As growing hyphae penetrate pulmonary tissues, they can invade the endothelial lining of nearby blood vessels and break off into circulation, causing sepsis and dissemination accompanied by thrombosis, hemorrhagic infarction and invasion of distant organs [8, 164”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fungal pathogens are responsible for at least 13 million infections and 1.5 million deaths globally per year, primarily in those with some compromised immune function [1].”
From Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 (2022) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“In healthy individuals, these conidia are rapidly cleared, but in the case of immunocompromised patients, conidia can germinate and develop filamentous hyphae [1, 166]. This fungal growth can result in invasive aspergillosis: a severe and aggressive fungal disease characterized by tissue damage, necrosis and hypoxia [8, 164, 167].”
From Mechanisms of fungal dissemination (2021) · cites this paper as [8]
In the citing paper
“Candida albicans the primary species responsible for mucosal disease”
From Acquisition of cross-azole tolerance and aneuploidy in Candida albicans strains evolved to posaconazole (2022) · cites this paper as Bongomin et al. 2017
In the citing paper
“Deep-seated candidiasis, arising from direct inoculation or hematogenous dissemination of Candida into normally sterile body sites, is often difficult to diagnose and may affect a population as large as that of candidemia [4,5,6].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“28,447 [2.5% of 1,136,092] (62 per 100,000) patients with ABPA”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“37,491 [3.33% of 1,136,092] (37.5 per 100,000) with severe asthma with fungal sensitisation (SAFS)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“Average incidence is 154 cases per 100,000 (SD ± 654)”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.5. Allergic Bronchopulmonary Aspergillosis (ABPA) & Severe Asthma with Fungal Sensitisation (SAFS)
“the highest incidence rates reported in United Kingdom (654 per 100,000)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“The total burden of candidaemia is 159,253 cases across these 39 countries with available data.”
§ Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision > 2. Estimate precision > 2.1. Candidaemia
“Europe (n = 1 country, 420,549 cases)”
Citations
Cites
Vos, T., Flaxman, A. D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., Aboyans, V., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61729-2 · Cited by 8,291
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundHidden Killers: Human Fungal Infections
Brown, G. D., Denning, D. W., Gow, N. A. R., Levitz, S. M., Netea, M. G., & White, T. C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004404 · Cited by 4,284 · cited 1×
“Pneumocystis jirovecii pneumonia is emerging as a leading cause of infection in HIV/AIDS patients [1].”
BackgroundSelf-citationGlobal burden of disease of HIV-associated cryptococcal meningitis: an updated analysis
Rajasingham, R., Smith, R. M., Park, B. J., Jarvis, J. N., Govender, N. P., Chiller, T. M., Denning, D. W., Loyse, A., & Boulware, D. R. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30243-8 · Cited by 1,861 · cited 1×
“[8], Fungal Infection Trust [12], Global Action Fund for Fungal Infection (GAFFI) Roadmap [9], and van de Sande [13].”
BackgroundSelf-citationGlobal asthma prevalence in adults: findings from the cross-sectional world health survey
To, T., Stanojevic, S., Moores, G., Gershon, A. S., Bateman, E. D., Cruz, A. A., & Boulet, L.-P. (2012) · BMC Public Health · doi:10.1186/1471-2458-12-204 · Cited by 1,521 · cited 1×
“6% respectively among individuals aged 18 to 45 years [142].”
BackgroundKullberg, B. J., & Arendrup, M. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1315399 · Cited by 1,315 · cited 1×
“Candidaemia is the most common form of invasive candidiasis associated with an unacceptably high mortality rates in excess of 40% even with the introduction of newer antifungal agents [30,32,33].”
BackgroundSobel, J. D. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60917-9 · Cited by 1,270
Marr, K. A., Carter, R. A., Boeckh, M., Martin, P., & Corey, L. (2002) · Blood · doi:10.1182/blood-2002-05-1496 · Cited by 957
(2006) · PubMed · Cited by 906
Research works printed but not linked: 6
- Denning, 2013, Global fungal Burden, Mycoses, 56, 13
- The Fungal Infection Trust (2011, January 18). How common are fungal diseases?. Proceedings of the Fungal Research Trust 20th Anniversary Meeting, London, UK. Available online: http://www.fungalinfectiontrust.org/wp-content/uploads/2015/12/How-Common-are-Fungal-Diseases-v12.2.pdf.
- Jayasekera, 2013, The burden of serious fungal infections in Sri Lanka, Mycoses, 56, 103
- Gugnani, 2017, Burden of serious fungal infections in Bangladesh, Eur. J. Clin. Microbiol. Infect. Dis., 36, 965, 10.1007/s10096-017-2921-z · DOI · Paper page
- Samayoa, B., Isern, V., Serra, L., Rivera, B.E., Nikiforov, M., Arathoon, E., Samayoa, C., Vallès, X., Prieto, L., and Álvarez, C. (2010, January 18–23). Preliminary results of a prospective cohort of HIV+ patients in Guatemala. Proceedings of the XVIII International AIDS Conference, Vienna, Austria.
- Gopinathan, 2002, The Epidemiological Features and Laboratory Results of Fungal Keratitis, Eye, 21, 555
Cited by
Items 1,501–1,600 of 2,931
Effects of efflux pumps on antifungal activity of chitosan against Candida albicans
Muangsawat, S., Chaiyosang, P., Sinkanarak, P., Sukted, J., Thanyasrisung, P., & Matangkasombut, O. (2024) · Journal of Oral Microbiology · doi:10.1080/20002297.2024.2357976 · Cited by 8
“Candida can cause superficial and invasive infections that affect millions of people worldwide, especially in immunocompromised persons [1].”
BackgroundTan, X. T., Mokhtar, N. N., Hii, S. Y. F., & Amran, F. B. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s452619 · Cited by 6
Genotypic diversity, virulence, and molecular genetic tools in Histoplasma
Sepúlveda, V. E., Goldman, W. E., & Matute, D. R. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00076-23 · Cited by 9
Severe Pneumocystis jirovecii pneumonia: time to reassess our practices
Nseir, S., Valadas, E., & Léone, M. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07547-9 · Cited by 7
“Although its incidence is quite low (less than five cases per 10,000 habitants annually) [2], admission to intensive care unit (ICU), which is a common outcome in these patients, is associated with a mortality rate reaching 50% [3].”
Basotra, S. D., Kumari, Y., Vij, M., Tyagi, A., Sharma, D., & Bhattacharyya, M. S. (2024) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.4c00155 · Cited by 7
Marsaux, B., Moens, F., Vandevijver, G., Marzorati, M., & de Wiele, T. V. (2024) · FEMS Microbiology Ecology · doi:10.1093/femsec/fiae113 · Cited by 9
“Among these fungi, sever al str ains can pose significant health risks to humans, r esulting in a global health burden (Bongomin et al. 2017 ).”
BackgroundBrouwer, C. P. J. M., Theelen, B., van der Linden, Y., Sarink, N., Rahman, M., Alwasel, S. H., Cafarchia, C., Welling, M. M., & Boekhout, T. (2024) · Antibiotics · doi:10.3390/antibiotics13080790 · Cited by 7
Cotter, C. J., & Trinh, C. T. (2024) · The CRISPR Journal · doi:10.1089/crispr.2024.0052 · Cited by 8
Lethal Synergistic Infections by Two Concurrent Respiratory Pathogens
Roe, K. (2024) · Archives of Medical Research · doi:10.1016/j.arcmed.2024.103101 · Cited by 8
Mixed-Metal 2D Chalcogenides MoxRe1–xS2 as Antifungal Near-Infrared-Responsive Nanozymes
Zhang, F., Sahani, R., An, C., Na, H., Oyon, S. A., Radu, D. R., McGoron, A. J., & Lai, C. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c05939 · Cited by 6
Safaat, M., Saputra, H., Santoso, P., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c19868 · Cited by 6
Li, Y., Ren, X., Wang, Q., Shen, S., Li, Y., Qian, X., Tang, Y., Jia, J., Zhang, H., Ding, J., et al. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s493019 · Cited by 6
Morais, I. D., Francelino, L. E. C., Leite, V. G. S., Martins, G. M., Vitoriano, J. D. O., Feijó, F. M. C., Santos, C. S., de Oliveira, M. F., Alves, C., & de Moura, C. E. B. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01422 · Cited by 9
Gil, G. A., Kakuda, L., Tonani, L., Kress, M. R. V. Z., & OLIVEIRA, W. P. D. (2025) · ACS Omega · doi:10.1021/acsomega.4c08578 · Cited by 8
Zhai, H., Zeng, J., Ma, X., Wang, F., Xu, W., Song, M., & Xu, W. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1562103 · Cited by 6
Molecular recognition of fungal methylated glucosylceramides by ETD151 defensin
Kharrat, O., Paquet, F., Nasreddine, R., Madinier, J., Nehmé, R., Aucagne, V., Bulet, P., Warschawski, D. E., & Landon, C. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110587 · Cited by 7
“However, recent data indicate that fungal pathogens infect billions of people and cause at least 1.5 million deaths annually (1, 2).”
InfluentialChandrasekaran, R., & Murugavel, S. (2019) · Structural Chemistry · doi:10.1007/s11224-019-01329-6 · Cited by 6
Gentechnik revolutioniert Diagnostik
Tietz, H. (2020) · Der Deutsche Dermatologe · doi:10.1007/s15011-020-3282-y · Cited by 6
Drawing a parallel between phytochemistry and other features of Vismieae species
Diel, K. A. P., Meirelles, G. D. C., Bridi, H., et al. (2021) · Phytochemistry Reviews · doi:10.1007/s11101-021-09740-w · Cited by 6
“Antifungal activity Fungal infections affect more than one billion of individuals worldwide, causing over 1.5 million of deaths per year (Bongomin et al. 2017).”
BackgroundInfluentialAllison, C. L., Moskaluk, A. E., VandeWoude, S., & Reynolds, M. M. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03225-7 · Cited by 8
“Chronic pulmonary aspergillosis (CPA) is most frequently seen in patients that have at one time had lung disease, such as tuberculosis, chronic obstructive pulmonary disease, or lung cancer [31].”
BackgroundPulmonary aspergilloma on transthoracic ultrasound
Ruby, L. C., Kadavigere, R., Sheshadri, S., Saravu, K., & Bélard, S. (2021) · Infection · doi:10.1007/s15010-021-01589-7 · Cited by 6
Identification of Dual-Target Compounds with Antifungal and Anti-NLRP3 Inflammasome Activity
Lowes, D. J., Miao, J., Al-Waqfi, R. A., Avad, K., Hevener, K. E., & Peters, B. M. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00270 · Cited by 7
Health threat caused by fungi of medical interest: where are we in 2021?
Désoubeaux, G., & Chesnay, A. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/4955 · Cited by 8
“Over 300,000 patients develop invasive aspergillosis yearly [1, 9]; the mortality still remains close to 30–50%, in spite of adequate antifungal therapies [3].”
BackgroundDrug repositioning of benzimidazole anthelmintics in the treatment of cryptococcosis: a review
de Oliveira, E. A. M., Ferreira, G. F., & Lang, K. L. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02824-4 · Cited by 7
“Currently, tamoxifen is in phase II clinical trial as an adjunct in the treatment of cryptococcal meningitis associated or not with AIDS [11, 12].”
BackgroundUnderstanding the genetic basis of immune responses to fungal infection
Gonçalves, S. M., Cunha, C., & Carvalho, A. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2022.2063839 · Cited by 6
“Owing to the inherent immune dysfunction caused by medical interventions such as hematopoietic stem-cell or solid organ transplantation, chemotherapy, and use of broadspectrum antibacterial or immunomodulatory therapies, the incidence of fungal infections is rising [1].”
BackgroundLamsal, S., Adhikari, S., Raghubanshi, B. R., Sapkota, S., Rijal, K. R., Ghimire, P., & Banjara, M. R. (2021) · Tribhuvan University Journal of Microbiology · doi:10.3126/tujm.v8i1.41195 · Cited by 8
“Three among four women during their lifetime are affected from candidiasis especially during their child bearing age (Bongomin et al 2017).”
BackgroundKaur, K., Singh, A., Kaur, R., Kaur, H., Kaur, R., Arora, S., & Bedi, N. (2023) · Archives of Microbiology · doi:10.1007/s00203-023-03426-x · Cited by 6
“Candida albicans is one of the most communal fungal pathogen responsible for 50–90% cases of systemic and superficial candidiasis in humans (Bongomin et al. 2017).”
BackgroundPinheiro, B. G., Pôssa, A. P., Ricci, G., Nishikaku, A. S., Hagen, F., Hahn, R. C., Camargo, Z. P. D., & Rodrigues, A. M. (2023) · Journal of Fungi · doi:10.3390/jof9030358 · Cited by 6
Yurtoğlu, S., Sarı, S., Kart, D., Sabuncuoğlu, S., & Saraç, S. (2023) · ChemistrySelect · doi:10.1002/slct.202300134 · Cited by 6
Lfitat, A., Ed‐Dahmani, I., Bousraf, F. Z., Belhaj, A., Ainane, T., Taleb, M., Gourch, A., & Abdellaoui, A. (2023) · Indonesian Food and Nutrition Progress · doi:10.22146/ifnp.79710 · Cited by 8
Zeeshan, M., Memon, S., Malick, A. A., Naqvi, S. F., Farooqi, J. Q., Ghanchi, N. K., & Jabeen, K. (2023) · Mycoses · doi:10.1111/myc.13677 · Cited by 6
Lim, S. J., Noor, N. D. M., Sabri, S., Ali, M. S. M., Salleh, A. B., & Oslan, S. N. (2023) · Medical Mycology · doi:10.1093/mmy/myad126 · Cited by 6
One Health Approach to Addressing Fungal Infection Disparities
Sengupta, M., Kundu, A., Nayak, G., Srivastava, S., & Banerjee, S. (2024) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00480-2 · Cited by 7
“The global HIV/AIDS pandemic has been closely associated with a rise in opportunistic fungal infections, such as esophageal and tracheobronchial invasive candidiasis, Pneumocystis pneumonia, cryptococcosis, and histoplasmosis [44].”
InfluentialAssessment of possible biomedical applications of green synthesized TiO2NPs-an in-vitro approach
Nga, N. T. A., Aafreen Fathima, H., & Alahmadi, T. A. (2024) · Environmental Research · doi:10.1016/j.envres.2024.118278 · Cited by 6
Hansanant, N., Cao, K., Tenorio, A., Joseph, T., Ju, M., McNally, N., Kummari, E., Williams, M. D., Cothrell, A., Buhrow, A. R., et al. (2024) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00777 · Cited by 8
Karakoyun, A. S., Spruijtenburg, B., Ünal, N., Meijer, E. F. J., Sucu, M., Polat, S. H., Meis, J. F. G. M., de Groot, T., & İlkit, M. (2024) · Medical Mycology · doi:10.1093/mmy/myae005 · Cited by 8
Ashmeik, W., Schirò, S., Joseph, G. B., et al. (2024) · Skeletal Radiology · doi:10.1007/s00256-024-04707-2 · Cited by 6
“Fungal infections are an important cause of morbidity and mortality responsible for at least 1.5 million deaths globally per year [1] and disproportionately impacting immunocompromised patients.”
InfluentialBoyer, J., Sedik, S., Egger, M., Dichtl, K., Prattes, J., Kriegl, L., Krause, R. G. E., Prüller, F., & Hoenigl, M. (2024) · Mycoses · doi:10.1111/myc.13756 · Cited by 6
Synthesis, characterization, in silico and antifungal studies of thiazolidine analogues
Abid, F. M. A., Jamalis, J., Chander, S., Wahab, R. A., Bhagwat, D., & Murugesan, S. (2019) · Chemical Data Collections · doi:10.1016/j.cdc.2019.100219 · Cited by 5
The Burden of Serious Fungal Infections in Tajikistan
Bobokhojaev, O., Osmanov, A., Aliev, S. P., Radjabzoda, A. S., Avgonov, Z. T., Manonov, S. T., & Denning, D. W. (2019) · Journal of Fungi · doi:10.3390/jof5030068 · Cited by 9
“More than 150 million people have serious fungal infections worldwide while the mortality associated with fungal infections is similar to tuberculosis and more than 3 times higher than the mortality from malaria [2].”
BackgroundSelf-citationBongomin, F., Erima, B., Kwizera, R., & Odongo-Aginya, E. I. (2020) · Education Research International · doi:10.1155/2020/9468241 · Cited by 5
Self-citationXu, X., Xia, C., & Huang, Y. (2020) · Immunobiology · doi:10.1016/j.imbio.2020.151996 · Cited by 6
Davies, G. E., Singh, O., Prattes, J., Hoenigl, M., Sheppard, P. W., & Thornton, C. R. (2020) · Journal of Fungi · doi:10.3390/jof7010019 · Cited by 6
“The estimated incidence of IPA is >300,000 cases/year, with more than 90% of the ~150,000 deaths annually caused by A. fumigatus [8].”
Identifying novel allergens from a common indoor mould Aspergillus ochraceus
Roy, S., Saha, B., & Gupta-Bhattacharya, S. (2021) · Journal of Proteomics · doi:10.1016/j.jprot.2021.104156 · Cited by 6
Markantonatou, A., Tragiannidis, A., Galani, V., Doganis, D., Antoniadi, K., Tsipou, H., Lambrou, M., Katzilakis, N., Paisiou, A., Palabougiouki, M., et al. (2021) · Journal of Fungi · doi:10.3390/jof7050357 · Cited by 6
Karuga, F. F., Góralska, K., & Brzeziańska‐Lasota, E. (2021) · Acta Mycologica · doi:10.5586/am.566 · Cited by 6
Bruno, M., Matzaraki, V., van de Veerdonk, F. L., Kumar, V., & Netea, M. G. (2021) · Infection and Immunity · doi:10.1128/iai.00005-21 · Cited by 6
Invasive Dermatophytoses: Clinical Presentations, Diagnosis, and Treatment
Durdu, M., & İlkit, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-67421-2_4 · Cited by 7
Molecular Umbrella as a Nanocarrier for Antifungals
Skwarecki, A. S., Martynow, D., Milewska, M. J., & Milewski, S. (2021) · Molecules · doi:10.3390/molecules26185475 · Cited by 6
Candida albicans Can Survive Antifungal Surface Coatings on Surfaces with Microcone Topography
Chakraborty, A., Jasieniak, M., Coad, B. R., & Griesser, H. J. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.1c00307 · Cited by 8
Toychiev, A., Belotserkovets, V., Игнатьев, Н. А., Madrakhimov, S., Shaislamova, M., & Osipova, S. (2022) · Tropical Doctor · doi:10.1177/00494755221110678 · Cited by 6
Schulz, J., Michelet, R., Zeitlinger, M. A., Mikus, G., & Kloft, C. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03292-0 · Cited by 6
Polymer-based particles against pathogenic fungi: A non-uptake delivery of compounds
Orasch, T., Gangapurwala, G., Vollrath, A., González, K., Alex, J., Luis, A. D. S., Weber, C., Hoeppener, S., Cseresnyés, Z., Figge, M. T., et al. (2023) · Biomaterials Advances · doi:10.1016/j.bioadv.2023.213300 · Cited by 8
Ashu, E. E., & Xu, J. (2018) · Genes · doi:10.3390/genes9070359 · Cited by 7
“Invasive aspergillosis is the most lethal type of aspergillosis and is estimated to affect >300,000 people globally every year, with a mortality rate as high as 90% in at-risk populations [1,36].”
BackgroundInfluentialFatal necrotising cutaneous mucormycosis due to novel Saksenaea species: a case study
Kachuei, R., Badali, H., Vaezi, A., Jafari, N. J., Ahmadikia, K., Kord, M., Aala, F., Al‐Hatmi, A. M. S., & Khodavaisy, S. (2021) · Journal of Wound Care · doi:10.12968/jowc.2021.30.6.465 · Cited by 6
Saleki, K., Razi, S., & Rezaei, N. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-818006-8.00007-4 · Cited by 7
Exposure to Fungi in Health Care Facilities
Sabino, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21034-0 · Cited by 9
Pellón, A., Nasab, S. D. S., Bidkhori, G., Vaga, S., Begum, N., Blagojevic, M., Singh, N. K., Griffiths, J. S., Kotowicz, N. K., Guennec, A. D. L., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2159406/v1 · Cited by 6
Gregor, J. B., Gutierrez-Schultz, V. A., Hoda, S., Baker, K. M., Saha, D., Burghaze, M. G., & Briggs, S. D. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.16.545382 · Cited by 5
“5 million deaths occurring annually worldwide (1, 2).”
BackgroundSchmidlin, K., Apodaca, S., Newell, D., Sastokas, A., Kinsler, G., & Geiler‐Samerotte, K. (2024) · eLife · doi:10.7554/elife.94144.1 · Cited by 7
Brown, A. C., Steenwyk, J. L., & Rokas, A. (2024) · G3 Genes Genomes Genetics · doi:10.1093/g3journal/jkae091 · Cited by 4
“IA is estimated to be responsible for over 400,000 infections per year with a mortality rate of > 50% (Bongomin et al .”
BackgroundVázquez-Muñoz, R., Thompson, A. K., Sobue, T., & Dongari‐Bagtzoglou, A. I. (2024) · mBio · doi:10.1128/mbio.02416-24 · Cited by 9
EGR1 regulates oral epithelial cell responses to Candida albicans via the EGFR- ERK1/2 pathway
Dickenson, R. E., Pellón, A., Ponde, N. O., Hepworth, O. W., Gatward, L. F. D., Naglik, J. R., & Moyes, D. L. (2024) · Virulence · doi:10.1080/21505594.2024.2435374 · Cited by 12
“However, under certain environmental conditions, this fungus can become pathogenic and cause superficial mucosal infections in otherwise healthy individuals (e.g. thrush), associated with high morbidity[5].”
Moussiegt, A., Donald, S. M., Bougnoux, M., Eer, M. V., Vreden, S., Chiller, T. M., Cáceres, D. H., Gómez, B. L., Nacher, M., Lortholary, O., et al. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107360 · Cited by 7
Khalid, A., Santhanam, J., Tzar, M. N., et al. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42245 · Cited by 5
“The global incidence of invasive fungal diseases (IFDs) is estimated to affect nearly 1.9 million patients annually, with a considerable number of these cases being life-threatening and resulting in over 1.6 million deaths each year [1].”
InfluentialAvailability and cost of antifungal therapy in Vietnam: A 5-year retrospective study
Kwang, Y. C., Nguyen, H. T., Alffenaar, J. C., et al. (2025) · Medical Mycology · doi:10.1093/mmy/myaf028 · Cited by 5
Stoyanova, M., Gledacheva, V., Milusheva, M., Todorova, M. M., Kircheva, N., Angelova, S., Stefanova, I. D., Pencheva, M. M., Tumbarski, Y. D., Vasileva, B., et al. (2025) · Nanomaterials · doi:10.3390/nano15110815 · Cited by 5
“Fungal illnesses cause about 1.6 million deaths annually, which is comparable to tuberculosis and more than three times the estimated number of deaths from malaria [17].”
InfluentialCaldera, J. R., Dayo, A., Wiederhold, N. P., & Yang, S. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.00291-25 · Cited by 8
Niemczyk, W., Kępa, M., Żurek, J., Aboud, A., Skaba, D. R., & Wiench, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14145111 · Cited by 7
“In the past 4 years, the Leading International Fungal Education (LIFE) portal has determined the global burden of severe fungal infections in over 80% of the current world population [8].”
Mateo, E. M., Mateo, F., Tarazona, A., & Jiménez, M. (2025) · Toxins · doi:10.3390/toxins17080378 · Cited by 7
Gao, Y., Wang, Z., Wang, X., Xu, Y., Luo, J., Li, S., Yang, Y., Yan, L., & Zou, X. (2025) · Mycobiology · doi:10.1080/12298093.2025.2537477 · Cited by 5
“Abnormal proliferation of C. albicans can lead to a range of diseases, including vaginitis and candidemia, which pose significant threats to human health [2].”
Anand, G., Lahariya, R., Priyadarshi, K., & Sarfraz, A. (2025) · Acta Clinica Belgica · doi:10.1080/17843286.2025.2546420 · Cited by 13
“…public health threat, particularly affecting individuals with pre-existing health conditions, compromised immune systems, critically ill ICUs patients, individuals undergoing invasive medical procedures, those receiving broad-spectrum antibiotics, and patients on immunosuppressive therapies [5].”
Biofilm development in three-dimensional models infected with Trichophyton rubrum
Mendonça, M. B., Cabral, A. K. L. F., Arantes, B. B. A., dos Santos, R. C., Medina‐Alarcón, K. P., dos Santos, K. S., Gualque, M. W. D. L., Fernandes, L. D. S., Belizário, J. A., Fuzinaga, T. Y. T., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.01087-25 · Cited by 8
“to affect approximately 20–25% of the global population (3).”
Kiaheyrati, N., Moaf, A. M. G., Manzari, M., Payravand, A., Sabzi, S., Samiee-Rad, F., & Babaei, A. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118624 · Cited by 6
Castro-Fuentes, C. A., Duarte-Escalante, E., León, M. G. F.-D., González-Villaseñor, M. D. C. A., & Reyes-Montes, M. D. R. (2025) · Journal of Fungi · doi:10.3390/jof11100720 · Cited by 5
Photoactivated antifungal polymers prepared by PET-RAFT polymerization
Gmedhin, H., Aquib, M., Corrigan, N. A., Lenardon, M. D., & Boyer, C. A. (2025) · Chemical Science · doi:10.1039/d5sc08534a · Cited by 7
Beyer, R., Zangl, I., Seidl, B., Pap, I.-J., Lackner, M., Strauss, J., Willinger, B., & Schüller, C. (2025) · mSystems · doi:10.1128/msystems.00786-25 · Cited by 9
Gawad, M. M. A. E., & Shady, R. M. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10405-4 · Cited by 7
“Patient compliance with long-term treatments and co-morbidities also affect therapeutic outcomes adversely [ 44].”
Fernandes, J. A. L., Zatti, M. D. S., Arantes, T. D., de Souza, M. F. B., Santoni, M. M., Rossi, D., Zanelli, C. F., Liu, X., Bagagli, E., & Theodoro, R. C. (2022) · Journal of Fungi · doi:10.3390/jof8080846 · Cited by 5
“5 million people per year and more than one billion individuals are currently living with a fungal infection [1].”
BackgroundJain, S. K., Kaur, M., Shivgotra, R., Bhardwaj, N., Saini, S., & Thakur, S. (2022) · Current Drug Targets · doi:10.2174/1389450124666221128122836 · Cited by 6
Synthesis, characterization, and biological activity of novel azole piperazine congeners
Sadalge, P. R., Karnawadi, V., Roy, L. D., Prabu, M., Krishnamurthy, G., Gour, P., Arland, S. E., & Kumar, J. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2023.58094 · Cited by 6
Kalimuthu, S., Pudipeddi, A., Braś, G., Tanner, J. A., Rąpała‐Kozik, M., Leung, Y. Y., & Neelakantan, P. (2023) · Apmis · doi:10.1111/apm.13322 · Cited by 6
“Fungal infections of the skin, mouth, and vagina affect approximately 135 million people worldwide, while invasive bloodstream infections have a 50% mortality rate [2].”
BackgroundCho, O., Takada, S., Odaka, T., Futamura, S., Kurakado, S., & Sugita, T. (2023) · Journal of Fungi · doi:10.3390/jof9070778 · Cited by 4
“As the number of immunocompromised hosts increases, the global incidence of bloodstream fungal infections is also rising, leading to candidiasis being recognized as one of the two major fungal diseases, along with aspergillosis [8,9].”
BackgroundFluorescent optotracers for bacterial and biofilm detection and diagnostics
Richter‐Dahlfors, A., Kärkkäinen, E., & Choong, F. X. (2023) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2023.2246867 · Cited by 7
Mass Spectrometry-based Proteomics of Eukaryotes
Geddes‐McAlister, J., Rizakos, T., & Muselius, B. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/bk9781837670338-00215 · Cited by 5
Clinico-Demographic Parameters of Oral Fungal Infections: An Institutional Retrospective Study
Devi, K. S., Ramasubramanian, A., & Kizhakkoottu, S. (2024) · Cureus · doi:10.7759/cureus.55386 · Cited by 5
“Only a few harmful fungi are aggressive and virulent enough to infect a healthy host [16].”
BackgroundGenetic modification of Candida maltosa, a non-pathogenic CTG species, reveals EFG1 function
Chávez-Tinoco, M., García-Ortega, L. F., & Mancera, E. (2024) · Microbiology · doi:10.1099/mic.0.001447 · Cited by 6
“Worldwide, these microorganisms are responsible for ~700 000 candidiasis cases every year, being an important part of the total number of infections caused by fungi and among the top health threats according to the World Health Organization [4, 5].”
Bregón-Villahoz, M., Menéndez-Manjón, P., Carrano, G., Díez, A., Arrieta-Aguirre, I., Fernandez-de-Larrinoa, Í., & Moragues, M. D. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116311 · Cited by 5
Spectrum and management of rare Candida /yeast infections in Kuwait in the Middle East
Ahmad, S., Asadzadeh, M., Al‐Sweih, N., & Khan, Z. (2024) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241263733 · Cited by 8
Deckers, C., Bélik, F., Khourssaji, M., Plum, P.-E., Ausselet, N., Bulpa, P., Sonet, A., Bihin, B., Huang, T., Denis, O., et al. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116493 · Cited by 6
Ansari, A., Kumar, D., Gupta, P., Poluri, K. M., Rai, N., Ameen, F., & Kumar, N. (2024) · Archives of Microbiology · doi:10.1007/s00203-024-04103-3 · Cited by 7
“…caused by C. albicans has become the most prevalent illness among hospitalised patients, giving rise to a critical condition known as candidemia which has been listed as the fourth most frequent cause of bloodstream infection (Pahwa et al. 2014; Bongomin et al. 2017 ; Weiner-Lastinger et al. 2020).”
Liu, Q., Chen, P., Xiao, D., Wei, J., Lin, Y., Tao, T., & Li, X. (2024) · Future Microbiology · doi:10.1080/17460913.2024.2423530 · Cited by 5
Cogliati, M., Buil, J. B., Esposto, M. C., Prigitano, A., Romanò, L., & Melchers, W. J. G. (2024) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2024.177923 · Cited by 5
Pavic, A., Radaković, N., Morić, I., Stankovic, N., Opsenica, D., & Šenerović, L. (2024) · npj Biofilms and Microbiomes · doi:10.1038/s41522-024-00608-3 · Cited by 5
Guimarães, J. G., de Campos, G. Y., Machado, M. P., Brito, P. K. M. O., dos Reis, T. F., Goldman, G. H., Palma, P. V. B., Fraga‐Silva, T. F. D. C., Umbelino, D. C., Venturini, J., et al. (2025) · Bioengineered · doi:10.1080/21655979.2025.2458786 · Cited by 7
Geremia, N., Bragato, B., Giovagnorio, F., Zuglian, G., Brugnaro, P., Solinas, M. L., Stano, P., Panese, S., & Parisi, S. G. (2025) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlaf044 · Cited by 6
From patterns to prediction: machine learning and antifungal resistance biomarker discovery
Thorn, V., & Xu, J. (2025) · Canadian Journal of Microbiology · doi:10.1139/cjm-2024-0248 · Cited by 6
Ma, Y., Wen, C., Duan, M., Yang, J., Wang, Y., Gao, L., Miao, G., & Feng, W. (2025) · Scientific Reports · doi:10.1038/s41598-025-98919-8 · Cited by 5
Maquera-Afaray, J., Cuellar, L. E., Cornely, O. A., Salmanton‐García, J., IFI Diagnostic and Treatment Capacity Collaborator Team Peru, Reategui, A. M., Flores, A. M. D., Sabogal, A. C., Pinedo, A. M. R., Candia, A. G. E., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.02020-24 · Cited by 8
Birštonas, L., Hortschansky, P., Bauer, I., Alcanzo, E. M., Kühbacher, A., Mertens, B., Müller, C., Brakhage, A. A., & Gsaller, F. (2025) · mBio · doi:10.1128/mbio.01854-25 · Cited by 5
Metadata
- Authors
- Bongomin, F., Gago, S., Oladele, R., & Denning, D.
- Affiliations
- University of Manchester (GB)
- Corresponding author
- Denning, David
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2017-10-18
- Volume
- 3
- Issue
- 4
- Pages
- 57
- ISSN
- 2309-608X (ISSN-L)
- PMC
- PMC5753159
- OpenAlex
- W2767031614
- Semantic Scholar
- a31bc4c8c2356520b0818d41b5c4a2e2091b6f32
- Cited by
- 2,953
- References
- 192
- Citations by year
- 2026: 280 · 2025: 388 · 2024: 518 · 2023: 436 · 2022: 427 · 2021: 370 · 2020: 307 · 2019: 156 · 2018: 67 · 2017: 2
- FWCI
- 22.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Fungi (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC/P002390/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, disease burden estimation, prevalence, chronic pulmonary aspergillosis, cryptococcal meningitis, invasive candidiasis, Pneumocystis carinii pneumonia, invasive aspergillosis, disseminated histoplasmosis, fungal asthma, fungal keratitis, HIV/AIDS, antifungal therapy, estimation accuracy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.